Raymond James Financial Services Advisors’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-9,197
Closed -$246K – 3343
2023
Q3
$246K Sell
9,197
-10,452
-53% -$357K ﹤0.01% 2791
2023
Q2
$728K Buy
19,649
+10,380
+112% +$362K ﹤0.01% 2115
2023
Q1
$289K Buy
9,269
+743
+9% +$23.9K ﹤0.01% 2663
2022
Q4
$254K Buy
8,526
+416
+5% +$14.9K ﹤0.01% 2694
2022
Q3
$309K Sell
8,110
-9,495
-54% -$476K ﹤0.01% 2549
2022
Q2
$960K Sell
17,605
-7,300
-29% -$401K ﹤0.01% 1867
2022
Q1
$1.55M Buy
24,905
+5,106
+26% +$336K ﹤0.01% 1665
2021
Q4
$1.99M Sell
19,799
-523
-3% -$46K ﹤0.01% 1537
2021
Q3
$1.83M Buy
20,322
+146
+0.7% +$13.3K ﹤0.01% 1536
2021
Q2
$1.86M Sell
20,176
-3,729
-16% -$298K ﹤0.01% 1508
2021
Q1
$2.31M Sell
23,905
-5,697
-19% -$588K 0.01% 1319
2020
Q4
$1.54M Buy
29,602
+143
+0.5% +$5.97K ﹤0.01% 1459
2020
Q3
$1.18M Sell
29,459
-8,086
-22% -$253K ﹤0.01% 1457
2020
Q2
$601K Buy
+37,545
New +$575K ﹤0.01% 1796

Other funds holding FLGT

Raymond James Financial Services Advisors's FLGT Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of Fulgent Genetics (FLGT) in Q4 2023, closing a stake of 9,197 shares — an estimated $246K sold.

Raymond James Financial Services Advisors first reported a position in FLGT in Q2 2020 and held it in 14 quarters. The position peaked at $2.31M in Q1 2021. 196 funds tracked by Wall St. Rank hold FLGT as of Q4 2023.

  • Raymond James Financial Services Advisors reported no remaining Fulgent Genetics position as of Q4 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 9,197 Fulgent Genetics shares in Q4 2023, an estimated $246K.
  • Raymond James Financial Services Advisors first reported a position in Fulgent Genetics in Q2 2020 and held it in 14 quarters.
  • Raymond James Financial Services Advisors's Fulgent Genetics position peaked at $2.31M in Q1 2021.
  • 196 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.